PPT-BP management Rationale for combination therapy

BP lowering Drug Efficacy Monotherapy Law MR et al BMJ 2003 Fall in BP mmHg Standard dose Twice standard dose Systolic BP Thiazides 88 103 β blockers 92 111 ACE inhibitors. Dr Glen Clack. Senior Medical Director. Oncology Translational Medicine Unit. AstraZeneca . Challenges and Opportunities. 2. Author | 00 Month Year. Set area descriptor | Sub level 1. Barriers Perceived by Pharma. Athos Bousvaros MD, MPH. Advances in IBD Dec 2014. Disclosures (last 12 months). Consultant. Takeda/Millennium. Dyax. Cubist. Peabody Arnold (litigation). Research support. Prometheus. Questions. Should we use combination therapy in our pediatric IBD patients?. CS410 – Software Engineering Lecture #18: Rationale Management. 1. Software Projects. You need to deliver the following things:. Project . Agreement (already completed). Program Overview. PAH Diagnostic Tools . PAH: Importance of Early Diagnosis to Improve Patient Outcomes . Diagnostic Algorithm for PH. Echocardiographic Probability of PH in Symptomatic Patients With a Suspicion of PH. Program Themes. Case 1. Case 1: Background and Diagnostics. Case 1: Assessment. Monotherapy vs Initial Combination Therapy? . AMBITION Trial. Patient-Centered Approach. Clinical Follow-Up of Patients With PAH. Program Goals. Complementary Mechanism of Action . . DPP-4 Inhibitors SGLT2 Inhibitors . Clinical Pearls. Fixed-Dose Combination Therapies. Using Fixed-Dose Combination Therapies to Achieve HbA. 1c. Program Goals. TECOS. Sitagliptin in Patients With T2D and Established CVD. FDA Drug Safety Communication. Guidelines: Initial Combination Therapy Recommendations. Fixed-Dose Combination Therapy. Rationale for Use. MARLON T. CO,MD. DISCLOSURE. Advisory board of Merck Philippines. Ps-DZ, 2009. Global Leading Risks for Death, 2010. Systolic blood pressure > 115 mmHg. Global Burden of Disease Study 2010 , . Lancet . Combination Therapy for Type 2 Diabetes September 2019, ©AACE, all rights reserved. Table of Contents Approach to Combination Therapy Agents Used in Combination Therapy Injectable Combination Therapies John Park, PGY1 . Hung IFN et al. ”Efficacy of clarithromycin-naproxen-oseltamivir combination in the treatment of patients hospitalized for influenza A(H3N2) infection: An open-label randomized, controlled, phase . 1C-January 2021An Attributionof Value Frameworkfor Combination Therapies Report by the Value Attribution Working GroupJanuary20212C-ANPROM/UK/PIP/0001January 2021AuthorsAndrew H Briggs12Alexis Doyle2J General Consideration Part . VI. . ……………………………………………………………………………………………………………………………………………………………………………………………………………………………………………. MAHTAB NIROOMAND M.D.. Assistant professor of Endocrinology. SBUMS. Tehran 1391/11/19. . Out-line . Pathophysiology. and types of dyslipidemia in diabetic patients. Benefits of lipid- lowering therapy. Disclosures. None.. Learning Objectives. Define Hormone Replacement Therapy and explain why it is used. Understand the typical presentation of menopause. Provide a differential diagnosis and management plan for a patient needing HRT.